Investors Purchase High Volume of Kodiak Sciences Put Options (NASDAQ:KOD)

Key Points

• Unusually heavy options activity: Investors purchased 21,273 Kodiak Sciences put options, roughly 1,361% above the typical volume of 1,456 contracts.
• Positive clinical results boosted prospects: Kodiak’s Zenkuda and tabirafusp-ted met primary endpoints in a Phase III wet-AMD trial, with results comparable to Eylea. The company plans to seek regulatory approval for Zenkuda.
• Shares surged and analyst targets rose: KOD jumped $57.29 to $89.64 on exceptionally high volume, while UBS, Lifesci Capital and HC Wainwright raised their price targets. Analysts’ consensus rating is “Moderate Buy,” with an average target of $87.33.

Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) was the recipient of unusually large options trading activity on Monday. Investors acquired 21,273 put options on the stock. This is an increase of approximately 1,361% compared to the typical volume of 1,456 put options.

Key Headlines Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Both drug candidates met the trial’s primary endpoints, with results indicating efficacy comparable to Regeneron’s established Eylea treatment. The outcome substantially improves Kodiak’s prospects of commercializing potential competitors in the large wet-AMD market. Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
• Positive Sentiment: Kodiak plans to seek regulatory approval for Zenkuda following the successful pivotal trial, providing a clearer path toward a potential product launch and future revenue. Kodiak Sciences Stock Pops After Eye-Disease Drugs Pass Key Trial
• Positive Sentiment: Analyst sentiment strengthened after the data release. UBS raised its price target from $80 to $120 and assigned a “buy” rating; Lifesci Capital increased its target from $85 to $145 and initiated an “outperform” view. HC Wainwright also lifted its target from $58 to $96 and reiterated a “buy” rating.
• Positive Sentiment: The trial success reverses some of the uncertainty surrounding Kodiak’s pipeline and has driven unusually heavy trading as investors reassess the company’s valuation and commercial potential. Kodiak doubles as resurrected eye disease drug matches Eylea in phase 3

Institutional Investors Weigh In On Kodiak Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KOD. Baker BROS. Advisors LP grew its stake in shares of Kodiak Sciences by 15.1% during the fourth quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company's stock worth $556,940,000 after acquiring an additional 2,608,696 shares during the last quarter. BlackRock Inc. acquired a new stake in Kodiak Sciences in the 2nd quarter worth approximately $161,113,000. Jupiter Topco LLC purchased a new stake in Kodiak Sciences during the 2nd quarter worth approximately $59,507,000. Janus Henderson Group PLC increased its stake in Kodiak Sciences by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 1,325,457 shares of the company's stock valued at $50,540,000 after purchasing an additional 325,457 shares in the last quarter. Finally, ICONIQ Capital LLC acquired a new position in Kodiak Sciences during the 2nd quarter valued at approximately $49,345,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Kodiak Sciences from $80.00 to $120.00 and gave the company a "buy" rating in a research note on Monday. Wall Street Zen downgraded shares of Kodiak Sciences from a "sell" rating to a "strong sell" rating in a research note on Saturday. Lifesci Capital upped their target price on Kodiak Sciences from $85.00 to $145.00 and gave the stock an "outperform" rating in a report on Monday. JPMorgan Chase & Co. boosted their price target on Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Finally, HC Wainwright upped their price objective on Kodiak Sciences from $58.00 to $96.00 and gave the stock a "buy" rating in a research note on Monday. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $87.33.

Kodiak Sciences Stock Performance

KOD traded up $57.29 during trading on Monday, hitting $89.64. The stock had a trading volume of 32,851,674 shares, compared to its average volume of 1,008,411. The stock has a 50 day simple moving average of $38.31 and a two-hundred day simple moving average of $37.34. Kodiak Sciences has a twelve month low of $10.94 and a twelve month high of $95.69. The company has a market capitalization of $5.63 billion, a PE ratio of -21.71 and a beta of 2.18.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.09). On average, equities research analysts anticipate that Kodiak Sciences will post -3.89 EPS for the current year.

About Kodiak Sciences

Kodiak Sciences Inc NASDAQ: KOD is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company's research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.